SCHEMBL10046210

SCHEMBL10046210

CON1C(=O)CC(S(=O)(=O)O)C1=O

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14474695 1.00
SCHEMBL31620917 0.85
SCHEMBL21129616 0.83 MMP2 (0.30)
SCHEMBL17324364 0.83
SCHEMBL13464156 0.82
SCHEMBL21664953 0.82
SCHEMBL23802491 0.81
SCHEMBL28430322 0.81
SCHEMBL28455486 0.81
SCHEMBL13445911 0.81

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024137619-A1 ANTI-CLAUDIN, BIS-BENZIMID AZOLE STING AGONIST IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2024-06-27 WO disclosed
WO-2024129956-A1 THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2024-06-20 WO disclosed
US-11826485-B2 Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) 2023-11-28 US disclosed
US-11739166-B2 Reactive polysaccharide-based hemostatic agent DAVOL INC. (US) 2023-08-29 US disclosed
WO-2022204536-A1 2-AMINO-4-CARBOXAMIDE-BENZAZEPINE IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2022-09-29 WO disclosed
WO-2022125884-A1 IMMUNOCONJUGATES COMPRISING AN ANTI-CEA ANTIBODY LINKED BY CONJUGATION TO ONE OR|MORE 8-HET-2- AMINOBENZAZEPINE DERIVATIVES USEFUL IN TREATING CANCER BOLT BIOTHERAPEUTICS, INC. (US) 2022-06-16 WO disclosed
WO-2022125908-A1 ANTI-PD-L1 IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2022-06-16 WO disclosed
WO-2022125891-A2 ANTI-CEA IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2022-06-16 WO disclosed
WO-2022125915-A1 ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2022-06-16 WO disclosed
WO-2022125904-A1 ANTI-HER2 IMMUNOCONJUGATES, AND USES THEREOF BOLT BIOTHERAPEUTICS, INC. (US) 2022-06-16 WO disclosed
US-20120082728-A1 MULTIFUNCTIONAL STEALTH NANOPARTICULES FOR BIOMEDICAL USE UNIVERSITE DE STRASBOURG (FR) 2012-04-05 US disclosed
US-20110111388-A1 METHOD FOR THE SENSITIVE DETECTION OF POLYAMINO ACIDS AND OTHER MACRO-MOLECULES XYNTEC CHEMIE GMBH WOLFEN (DE) 2011-05-12 US disclosed
US-20110111388-A1 METHOD FOR THE SENSITIVE DETECTION OF POLYAMINO ACIDS AND OTHER MACRO-MOLECULES XYNTEC CHEMIE GMBH WOLFEN (DE) 2011-05-12 US disclosed
US-20100069927-A1 Polymeric Masking Materials for Spanning Wound Sites, and Methods of Use Thereof HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) 2010-03-18 US disclosed
US-20090312530-A1 Processes for the convergent synthesis of calicheamicin derivatives WYETH (US) 2009-12-17 US disclosed
US-20070196454-A1 Crosslinked gels comprising polyalkyleneimines, and their uses as medical devices HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) 2007-08-23 US disclosed
US-20070197455-A1 Processes for the convergent synthesis of calicheamicin derivatives WYETH (US) 2007-08-23 US disclosed
EP-1198254-B1 CARRIER-DRUG CONJUGATE KTB TUMORFORSCHUNGS GMBH (DE) 2007-08-15 EP disclosed
US-7176256-B2 Reacting by crosslinking a first synthetic polymer containing multiple nucleophilic groups such as amino groups, with a second synthetic polymer containing multiple electrophilic groups such as succinimidyl groups to covalently bind them; use to prevent surgical adhesions, coat implants ANGIOTECH PHARMACEUTICALS (US), INC. (US) 2007-02-13 US disclosed
WO-2007001926-A2 LOW-SWELLING HYDROGEL SEALANTS FOR WOUND REPAIR HYPERBRANCH MEDICAL TECHNOLOGY, INC. (US) 2007-01-04 WO disclosed